stoxline Quote Chart Rank Option Currency Glossary
Femasys Inc. (FEMY)
1.18  0.01 (0.85%)    05-30 16:00
Open: 1.18
High: 1.22
Volume: 138,082
Pre. Close: 1.17
Low: 1.17
Market Cap: 26(M)
Technical analysis
2024-05-30 4:41:27 PM
Short term     
Mid term     
Targets 6-month :  1.6 1-year :  1.76
Resists First :  1.37 Second :  1.5
Pivot price 1.26
Supports First :  1.15 Second :  0.96
MAs MA(5) :  1.21 MA(20) :  1.28
MA(100) :  1.34 MA(250) :  1.04
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  4.9 D(3) :  9.8
RSI RSI(14): 40.1
52-week High :  4.75 Low :  0.24
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ FEMY ] has closed above bottom band by 11.3%. Bollinger Bands are 58.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.22 - 1.23 1.23 - 1.23
Low: 1.15 - 1.16 1.16 - 1.17
Close: 1.17 - 1.18 1.18 - 1.19
Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Headline News

Fri, 17 May 2024
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy ... - GlobeNewswire

Thu, 09 May 2024
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update - GlobeNewswire

Thu, 09 May 2024
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Thu, 02 May 2024
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

Thu, 04 Apr 2024
Femasys is committed to providing women with revolutionary healthcare products: CEO - AlphaStreet

Wed, 03 Apr 2024
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Instruments & Supplies
Shares Out 0 (M)
Shares Float 22 (M)
Held by Insiders 1.987e+007 (%)
Held by Institutions 7.5 (%)
Shares Short 1,120 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.402e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 87.8 %
Return on Equity (ttm) -40.7 %
Qtrly Rev. Growth 1.07e+006 %
Gross Profit (p.s.) 0.04
Sales Per Share 0.07
EBITDA (p.s.) -0.69
Qtrly Earnings Growth -1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 16.54
Price to Cash Flow -3.84
Stock Dividends
Dividend 0
Forward Dividend 1.19e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android